Regen BioPharma Inc

Regen BioPharma, Inc. is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space. The company is developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. Its principal products under development include HemaXellarate I, HemaXellerate II, dCellVax, and DiffronC. HemaXellerate I is a cellular therapeutic product indicated for the treatment of damaged bone marrow, which is manufactured using cells collected from the adipose tissue. HemaXellerate II is a version of HemaXellerate that is a universal donor endothelial cell-based therapeutic. dCellVax is a cellular therapy that improves the immune system through the process of gene silencing. DiffronC addresses molecular causes that block differentiation. The company, founded in 2012, is a wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. Regen BioPharma operates in the biotechnology and healthcare industries. The company's dedication to pursuing regenerative medicine solutions and developing innovative therapies for complex medical conditions positions it as a compelling prospect for venture capital investment. The potential of its products, such as HemaXellarate I and dCellVax, to address critical medical needs, especially in the treatment of damaged bone marrow and cancer, presents an attractive investment opportunity. With a strong focus on the burgeoning field of regenerative medicine and a diversified development pipeline, Regen BioPharma offers promising potential for growth and positive impact in the biotechnology and healthcare sectors.